Crossmark

Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients

Crossref DOI link: https://doi.org/10.1007/s11845-022-03204-6

Published Online: 2022-11-07

Published Print: 2023-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cai, Jianfei

Jiang, Yinghui

Chen, Fucai

Wu, Shubin

Ren, Hongjun

Wang, Pingping

Wang, Jiayong

Liu, Wei https://orcid.org/0000-0002-7652-3081
License Information

Text and Data Mining valid from 2022-11-07

Version of Record valid from 2022-11-07
More Information

Article History

Received: 26 September 2022

Accepted: 25 October 2022

First Online: 7 November 2022

Declarations

:

: The study was permitted by the Ethics Committee of Shanghai Qiangzhi Hospital.

: Each subject signed the informed consent.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below